Motexafin lutetium explained
Motexafin lutetium is a texaphyrin, marketed as Antrin by Pharmacyclics Inc.
It is a photosensitiser for use in photodynamic therapy to treat skin conditions and superficial cancers.
It has also been tested for use in photoangioplasty (photodynamic treatment of diseased arteries).[1]
It is photoactivated by 732 nm light which allows greater depth of penetration.[2]
Clinical trials
Phase II clinical trials were in progress in 1999.[3]
A phase I trial for prostate cancer reported in 2009.[4]
Notes and References
- http://www2.prnewswire.com/cgi-bin/stories.pl?ACCT=104&STORY=/www/story/09-25-2002/0001806282&EDATE= Pharmacyclics Announces Final Phase 1 Results of Antrin Phototherapy For Coronary Artery Disease
- http://findarticles.com/p/articles/mi_qa3931/is_200909/ai_n42040200/pg_9/ Porphyrin and Nonporphyrin Photosensitizers in Oncology: Preclinical and Clinical Advances in Photodynamic Therapy Photochemistry and Photobiology, Sep/Oct 2009. by O'Connor, Aisling E, Gallagher, William M, Byrne, Annette T
- http://ir.pharmacyclics.com/releasedetail.cfm?ReleaseID=141812 Antrin Photoangioplasty Phase II Clinical Trial Patient Treated During Live Case Demonstration at TCT
- 18676760 . 2008 . Patel . H . Mick . R . Finlay . J . Zhu . TC . Rickter . E . Cengel . KA . Malkowicz . SB . Hahn . SM . Busch . TM . Motexafin lutetium-photodynamic therapy of prostate cancer: Short and long term effects on PSA . 14 . 15 . 4869–76 . 10.1158/1078-0432.CCR-08-0317 . 2680073 . Clinical Cancer Research .
